Table 2. Stability Test Results (Particle Size as nm, PdI and ζ Potential as mV) of PLA/PVA/Atezolizumab Nanoparticle Formulations Prepared Using the Solvent Evaporation Method at the Initial Stage and 1st, 3rd, 6th, and 12th Months.
| Tinitial | T1month | T3month | T6month | T12month | |
|---|---|---|---|---|---|
| 5 ± 3 °C | 248.7 ± 2.116 nm | 250.7 ± 0.990 nm | 240.3 ± 2.916 nm | 254.3 ± 2.023 nm | 252.9 ± 1.058 nm |
| 0.132 ± 0.084 | 0.038 ± 0.050 | 0.179 ± 0.050 | 0.150 ± 0.048 | 0.097 ± 0.043 | |
| –2.15 ± 0.27 mV | –1.65 ± ± 0.04 mV | –13.9 ± 1.98 mV | –5.1 ± 1.04 mV | –3.7 ± 1.98 mV | |
| 25 ± 5 °C | 248.7 ± 2.116 nm | 256.1±0.450 nm | 282.4 ± 1.556 nm | 290.6 ± 2.476 nm | 299.4 ± 1.842 nm |
| 0.132 ± 0.084 | 0.045 ± 0.030 | 0.072 ± 0.076 | 0.104 ± 0.040 | 0.110 ± 0.078 | |
| 60 ± 5% | –2.15 ± 0.27 mV | –0.31 ± 0.21 mV | –1.79 ± 0.38 mV | –3.75 ± 0.72 mV | –5.48 ± 1.76 mV |
| 40 ± 5 °C | 248.7 ± 2.116 nm | 273.2 ± 1.875 nm | 293.2 ± 0.141 nm | 300.8 ± 2.548 nm | 323.8 ± 3.261 nm |
| 0.132 ± 0.084 | 0.085 ± 0.053 | 0.078 ± 0.037 | 0.102 ± 0.048 | 0.151 ± 0.062 | |
| 75 ± 5% | –2.15 ± 0.27 mV | –3.08 ± 1.04 mV | –1.23 ± 0.15 mV | –3.56 ± 0.09 mV | –5.32 ± 0.23 mV |